Cachexia is a condition known as wasting disorder, which causes extreme weight loss and muscle wasting. It is a symptom of various chronic conditions, such as cancer, chronic renal failure, COPD, HIV or AIDS, and multiple sclerosis. The difference between cachexia and other types of weight loss is that it isn’t involuntary. People who developed cachexia, don’t lose weight because they’re trying to trim down with diet or exercise, but because they eat less due to a diversity of reasons. Simultaneously, their metabolism changes, which causes their body to break down too much muscle.
According to the research article published by Journal of Cachexia, Sarcopenia and Muscle, it is estimated that over 160,000 people in the United States visit the hospital with a cachexia diagnosis every year, with approximately 1.5–2 million cachexia-related deaths per year, across the globe. Several approaches to develop cachexia and muscle wasting treatments have failed to be successful in phase III clinical trials, but new approaches are currently in development. Given the high prevalence and very high mortality associated with cachexia, advances are urgently needed for patients worldwide.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence